Stockscreener 앱 받기
0.6984
0.13%
-0.0009
시장 영업 전:
.70
0.0016
+0.23%
전일 마감가:
$0.6993
열려 있는:
$0.67
하루 거래량:
9,893
Relative Volume:
0.35
시가총액:
$28.53M
수익:
$15.12M
순이익/손실:
$-52.48M
주가수익비율:
-0.5404
EPS:
-1.2924
순현금흐름:
$-36.52M
1주 성능:
+0.69%
1개월 성능:
+2.77%
6개월 성능:
-2.87%
1년 성능:
-20.64%
1일 변동 폭
$0.67
$0.704
1주일 범위
$0.6403
$0.74
52주 변동 폭
$0.512
$2.92
Barinthus Biotherapeutics Plc Adr Stock (BRNS) Company Profile
명칭
Barinthus Biotherapeutics Plc Adr
전화
44 (0) 1865 818808
주소
20400 CENTURY BLVD, GERMANTOWN
Compare BRNS vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BRNS
Barinthus Biotherapeutics Plc Adr
|
0.6984 | 28.61M | 15.12M | -52.48M | -36.52M | -1.2924 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Barinthus Biotherapeutics Plc Adr Stock (BRNS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-05-25 | 개시 | Jefferies | Buy |
| 2021-05-25 | 개시 | Morgan Stanley | Overweight |
| 2021-05-25 | 개시 | William Blair | Outperform |
| 2021-05-24 | 개시 | H.C. Wainwright | Buy |
Barinthus Biotherapeutics Plc Adr 주식(BRNS)의 최신 뉴스
Bionano Genomics (BNGO) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
BeOne Medicines Ltd.Sponsored ADR (ONC) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance
Bain Capital Specialty (BCSF) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Barinthus Biotherapeutics shareholders approve scheme of arrangement - Investing.com
MARKER THERAPEUTICS (MRKR) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
What Makes Biorestorative Therapies (BRTX) a New Buy Stock - Yahoo Finance
Are KW, BRNS, AFBI Obtaining Fair Deals for their Shareholders? - Morningstar
USANA Health (USNA) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Why Qualcomm Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket - Sahm
Barinthus Biotherapeutics (NASDAQ: BRNS) cuts Q1 loss while pursuing Clywedog merger - Stock Titan
What Makes Haleon PLC Sponsored ADR (HLN) a New Buy Stock - Yahoo Finance
Why Brainsway (BWAY) Might be Well Poised for a Surge - Yahoo Finance
ProShares Russell 2000 Dividend Growers ETF $SMDV Shares Sold by Capital Investment Advisors LLC - Defense World
All You Need to Know About Theravance Bio (TBPH) Rating Upgrade to Strong Buy - Yahoo Finance
Are NSA, ULY, ESQ, BRNS Obtaining Fair Deals for their Shareholders? - Finviz
12 Health Care Stocks Moving In Friday's Pre-Market Session - Sahm
Biofrontera Inc. (BFRI) Upgraded to Buy: Here's Why - Yahoo Finance
Haleon PLC Sponsored ADR (HLN) Moves to Buy: Rationale Behind the Upgrade - Yahoo Finance
Banco Santander-Brazil (BSBR) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Sarepta Therapeutics (SRPT) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Short Interest in Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) Grows By 72.8% - Defense World
BioHarvest Sciences Inc. (NASDAQ:BHST) Sees Large Increase in Short Interest - Defense World
Arbutus (ABUS) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Viatris (VTRS) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Lowe’s Companies, Inc. $LOW Shares Acquired by Arbor Investment Advisors LLC - Defense World
Barinthus Biotherapeutics PLC sponsored ADR (BRNS) upgraded to buy: What does it mean for the stock? - MSN
Biohaven Ltd. (BHVN) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Should I buy Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) - Zacks Investment Research
Barinthus Bio reports positive initial data from celiac therapy trial - Investing.com
Halper Sadeh LLC Encourages BRNS, FITB, ADVM, HBAN Shareholders to Contact the Firm to Discuss Their Rights - Finviz
Barinthus Bio joins forces with metabolic disease biotech in reverse merger - Fierce Biotech
Liminatus Pharma (LIMN) Short Interest & Short Float | Updated Apr 2026 - MarketBeat
Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
BioCryst (BCRX) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance
Improved Revenues Required Before Barinthus Biotherapeutics plc (NASDAQ:BRNS) Stock's 29% Jump Looks Justified - Sahm
Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) Upgraded to Strong Buy: Here's Why - Nasdaq
Mexico Shingles Vaccine Market Size & Outlook, 2025-2030 - Grand View Research
Asia Pacific Shingles Vaccine Market Size & Outlook, 2030 - Grand View Research
Europe Shingles Vaccine Market Size & Outlook, 2025-2030 - Grand View Research
North America Shingles Vaccine Market Size & Outlook, 2030 - Grand View Research
What is the current Price Target and Forecast for Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) - Zacks Investment Research
Middle East & Africa Shingles Vaccine Market Size & Outlook, 2030 - Grand View Research
Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket - Investing.com UK
Barinthus Biotherapeutics (BRNS) Stock Forecast and Price Target 2026 - MarketBeat
Barinthus Biotherapeutics plc (BRNS) stock price, news, quote and history - Yahoo Finance UK
Barinthus Bio reports mixed results in APOLLO trial - Investing.com
Barinthus Biotherapeutics plc ADR Each Rep 1 Ord Share Spon share price - Hargreaves Lansdown
Barinthus Biotherapeutics plc (BRNS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Barinthus Biotherapeutics (BRNS) Stock Price, News & Analysis - MarketBeat
Barinthus Biotherapeutics (BRNS) 10K Form and Latest SEC Filings 2026 - MarketBeat
Barinthus Biotherapeutics Plc Adr (BRNS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.60%
0.94%
자본화:
|
볼륨(24시간):